Sistema de Salut de Catalunya
[Brunet-Mas E] Servei d'Aparell Digestiu, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Departament de Medicina, Universitat Autònoma de Barcelona, Sabadell, Spain. CIBERehd, Instituto de Salud Carlos III, Madrid, Spain. [Garcia-Sagué B, Melcarne L, Frisancho L] Servei d'Aparell Digestiu, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Departament de Medicina, Universitat Autònoma de Barcelona, Sabadell, Spain. [Vela E] Unitat d'Informació i Coneixement, Servei Català de la Salut, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Digitalization for the Sustainability of the Healthcare System (DS3), Barcelona, Spain. [Pontes C] Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Departament de Farmacologia, de Terapéutica i de Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain
Departament de Salut
2025-09-19T07:31:09Z
2025-09-19T07:31:09Z
2025-08-12
Epidemiology; Psychological endpoints; Quality of life; Socio-economical
Epidemiología; Criterios de valoración psicológicos; Calidad de vida; Socioeconómicos
Epidemiologia; Criteris d'avaluació psicològics; Qualitat de vida; Socioeconòmic
The prevalence of inflammatory bowel disease (IBD) is increasing worldwide, while the incidence is tending to stabilize. Moreover, the use of biological treatments is increasing; some studies suggest that surgeries and hospitalizations are decreasing instead. Methods: A population-based, retrospective cohort study was conducted using data from the Catalan Health Surveillance System (CHSS). All patients diagnosed with IBD were included between 2017 and 2023. Crude incidence and prevalence rates were calculated for the Catalan population. Data on pharmacological therapy, surgical procedures, hospitalizations, and mortality were analyzed. Trends in age-sex-adjusted rates were also estimated, and logistic regression was used to calculate the adjusted mortality odds ratio (OR). Data for Crohn's disease (CD) and ulcerative colitis (UC) were analyzed separately. Results: The number of prevalent IBD cases rose from 28,752 in 2017 to 41,423 in 2023. Despite incidence rates remaining stable (30.8 in 2017 and 29.9 per 100,000 inhabitants in 2023), prevalence rates increased (386.9 and 510.9 per 100,000 inhabitants, respectively). The use of biologics significantly increased (from 13.5% in 2017 to 21.0% in 2023), particularly ustekinumab and vedolizumab. In parallel, a decline in the use of immunosuppressants was observed. IBD-related surgeries and hospitalizations decreased during the study period, particularly among CD patients. Mortality remained low but was higher among IBD patients compared to the general population. Conclusions: The incidence of IBD in Catalonia has stabilized, while its prevalence continues rising, suggesting a transition to Stage 3 (compounding prevalence). The use of biological treatments is increasing steadily, whereas rates of surgeries and hospitalizations are consistently decreasing.
This study was supported by CIBERehd.
Article
Published version
English
Còlon irritable; Crohn, Malaltia de; Intestins - Inflamació; DISEASES::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases; DISEASES::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease; DISEASES::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Colitis::Colitis, Ulcerative; ENFERMEDADES::enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal; ENFERMEDADES::enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn; ENFERMEDADES::enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::colitis::colitis ulcerosa
MDPI
Journal of clinical medicine;14(16)
https://www.doi.org/10.3390/jcm14165711
Attribution-NonCommercial 4.0 International
https://creativecommons.org/licenses/by/4.0/
